Cencora (COR) Stock May Be 38% Undervalued As Cash Flow Holds Up

Cencora stock has delivered strong long term returns over the past five years, yet the current share price still screens as cheap relative to its intrinsic value estimate and traditional valuation multiples. With both the Discounted Cash Flow (DCF) model and the market based checks pointing in the same direction, investors are weighing how much of Cencora's story is already reflected in the price.

• Cencora has returned 171.7% over the past five years, which puts the recent valuation signals in sharper focus for long term holders.
• Expectations for continued cash generation can support the current pricing, while any pressure on margins or working capital needs may weigh on what investors are willing to pay.
• The company scores highly on Simply Wall St's valuation checks, and is flagged as undervalued in 5 of 6 tests, which suggests the broader framework leans toward Cencora trading below its estimated worth.

The stock's next move may depend on whether the current discount to intrinsic value and multiples persists as investors reassess what a fair price for Cencora should be.

Find out why Cencora's 8.8% return over the last year is lagging behind its peers.

Is Cencora Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at the cash Cencora can generate for shareholders and discounts it back to today. On the latest twelve month numbers, Cencora produced free cash flow of about $1.66b, and the model assumes those cash flows keep growing rather than shrinking over time.

On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $502 per share. Compared with the current share price, this implies the stock trades at roughly a 38.0% discount to that intrinsic value estimate. This is a meaningful gap for a business that is already generating substantial cash.

Overall, the Discounted Cash Flow (DCF) work suggests Cencora stock currently appears undervalued relative to its estimated intrinsic worth.

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 38.0%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Cencora.

Does Cencora Look Undervalued on Earnings?

P/E is a useful lens for Cencora because the company does generate earnings and is covered by analysts who track its profit profile closely. It helps you compare what the market is paying for each dollar of Cencora's earnings against other healthcare stocks.

Cencora currently trades on a P/E of about 23.8x. That sits below both the healthcare industry average of roughly 25.0x and the peer group average of about 28.6x. The Fair Ratio, which reflects what might be expected given Cencora's business profile and risk factors, sits higher at around 27.1x. That is a meaningful gap to the current P/E and indicates the market is assigning a lower earnings multiple than this framework would imply.

This kind of discount can persist, but it also gives existing and prospective shareholders a reference point for how the stock is priced relative to its earnings power and peer group.

On the P/E multiple alone, Cencora stock currently appears undervalued compared with where this model suggests it could trade.

See what the numbers say about this price — find out in our valuation breakdown.

The Cencora Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation puzzle for Cencora leaves off by spelling out which paths for Cencora's growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than it is today. Each narrative links its number to a clear view on how growth, profitability and risks might evolve, giving you something specific to revisit as fresh information on the company comes through.

Cencora inspires two very different stories, and the gap between them is wide enough that investors are paying close attention to the details.

Bull case: 11% undervalued

"Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time…"

Read the full Bull Case to see why Cencora could be undervalued

Bear case: roughly fairly valued

"While Cencora is embedding AI tools and broader digital capabilities across its highly automated distribution network, the ongoing cost and complexity of these investments could limit the benefit to operating margin if efficiency gains or service upsell do not keep pace with spending…"

Read the full Bear Case to see why Cencora could be overvalued

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

The Bottom Line

Cencora screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the P/E multiple checks, which all point in the same direction. The broad valuation framework also leans supportive, so the key question now is whether that gap to intrinsic value and peer multiples closes or persists.

For investors, the crux of the Cencora debate is whether its cash generation and margins can support a higher earnings multiple over time. If the company can sustain that profile without pressure from costs or working capital, the current discount may look like an opportunity rather than a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com